Recently, Beijing Jianyi Bao Technology Co., Ltd. and AstraZeneca China reached a strategic cooperation to jointly launch the "Medication at Will" retail chronic disease commercial insurance project. This innovative retail payment model transforms traditional drug purchasing into a "medicine + insurance + health management" service plan. Patients can not only enjoy a more economical and convenient medication experience but also receive diversified services such as disease progression protection and chronic disease health management.
△Launch Ceremony of the "Medication at Will" Retail Chronic Disease Commercial Insurance Project
△Left: Wang Lei, Executive Vice President, International Business and China President of AstraZeneca; Right: Zhang Shengming, Founder of Jianyi Bao
At the project launch ceremony held on July 1st, Wang Dong, Vice President and Head of Retail Business at AstraZeneca China, said: "AstraZeneca, starting from the needs of patients, has been continuously exploring innovative payment models with partners. Commercial insurance, as an important supplement to the current medical system, will have a profound impact on Chinese citizens, retail pharmacies, and the entire medical industry. AstraZeneca hopes that through the exploration of innovative retail payment models with Jianyi Bao, we can provide an innovative model for the integration of insurance, medical care, and health management, empowering the comprehensive service capabilities of retail pharmacies and benefiting more patients."
The "Medication at Will" retail chronic disease commercial insurance project covers AstraZeneca's cardiovascular and metabolic disease treatment areas. Jianyi Bao, in collaboration with AstraZeneca and chain pharmacies, has opened up a commercial insurance direct settlement system, reducing the economic burden on patients and improving their ability to pay for medical care; at the same time, it improves patients' awareness of standardized medication, leading to more effective long-term health management and delaying disease progression.
It is understood that after patients bring their prescriptions to the pharmacy and the pharmacist approves them, they only need to follow the "Medication at Will" official account, pay the fee once, and after becoming a health management member, they can enjoy related benefits, including annual commercial insurance direct settlement for medication, exclusive coverage for 6 common complications with a maximum coverage of 5,000 yuan (or general practice family doctor services), and health management services.
It is reported that the "Medication at Will" retail chronic disease commercial insurance project is expected to cover more than 200 chain pharmacies, benefit more than 160,000 patients, and save them more than 100 million yuan in drug expenses. This project plans to integrate with Huiyi Tianxia and e-commerce platforms in the future, expanding to more disease areas and benefiting more patients.
As a leading domestic expert in risk management for people with pre-existing conditions, Jianyi Bao improves the accessibility of innovative drugs through commercial insurance, providing comprehensive protection for people with pre-existing conditions, mainly chronic disease patients, and reducing their economic burden. Coupled with a series of health management services, Jianyi Bao and AstraZeneca are jointly helping to improve the chronic disease management service capabilities of retail pharmacies and meet the health management needs of patients.
According to Zhang Shengming, founder of Jianyi Bao, Jianyi Bao is actively integrating resources in the big health industry and relying on its expertise in medical data integration and insurance innovation to connect chain pharmacies, tertiary hospitals, and other patient-terminal medical scenarios. This creates a diversified medical security system centered on people with pre-existing conditions, achieving mutual benefit and win-win results for pharmaceutical companies, insurance companies, and medical scenarios. To date, Jianyi Bao has cooperated with several of the world's top ten pharmaceutical companies, its business covers more than 300 cities nationwide, and it has established cooperation with approximately 500 large chain brands, connecting over 160,000 pharmacy stores, with more than 4 million people having benefited from the professional protection and health management services provided by Jianyi Bao.
Jianyi Bao was founded in 2017. As a new generation of medical security solution platform for people with pre-existing conditions, Jianyi Bao connects pharmaceutical companies, medical channels, and financial insurance companies, developing innovative insurance products to address the pain points of cross-border cooperation among the three parties and solve the health security problems of people with pre-existing conditions, building a comprehensive insurance service platform serving 450 million people with pre-existing conditions.
In December 2019, China Zhongji Investment completed its investment in Jianyi Bao.
